Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (CATCH-ALL, CATCH-ALL, CATCH-ALL, CATCH-ALL)
José Carreras Leukämie-Stiftung (01R/2016)
Received: 20 December 2021
Accepted: 23 March 2022
First Online: 9 April 2022
: MBr received personal fees from Incyte (advisory board) and Roche Pharma AG, financial support for reference diagnostics from Affimed and Regeneron, grants and personal fees from Amgen (advisory board, speakers bureau, travel support), and personal fees from Janssen (speakers bureau), all outside the submitted work. The remaining authors declare no competing financial interests. None of the remaining authors has a relevant conflict of interest.